We are excited to inform you about two great speakers who will be visiting UNC during the first week of November.
Department of Pharmacology Graduate Students present:
The Luminary Scientist – Distinguished Lecture Series
Tuesday, November 3; 4:00 – 5:00 pm, 1131 Bioinformatics
Jeffrey Engelman, MD, PhD
Director: Molecular Therapies,
Massachusetts General Hospital Cancer Center
“Overcoming Resistance to Targeted Therapies: Challenges and Opportunities”
Dr. Engelman’s research has focused on developing strategies to perturb signal transduction to treat cancers. These studies have focused on receptor tyrosine kinases, the PI3K and MAPK signaling pathways, and the BH3 family members regulating apoptotic responses. In particular, his work has emphasized understanding the basis for sensitivity and resistance to kinase inhibitors in cancers. More recently, his research has explored the variety of mechanisms employed cancers to become resistant to eective targeted therapies. His work encompasses both laboratory models and clinical specimens. The goal of this research is to unleash the full potential of targeted therapies to improve the lives of patients with cancer.
Dr. Engelman received his Bachelor of Arts in Chemistry from Northwestern University and his MD and PhD degrees from the Albert Einstein College of Medicine. Dr. Engelman completed his medical residency in Internal Medicine at Brigham and Women’s Hospital and a fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. He joined the Harvard Medical School faculty and Massachusetts General Hospital in 2005. Dr. Engelman was elected a member of the American Society for Clinical Investigation in 2011. Named one of World’s Most Inuential Scientic Minds in 2014 by Thomson-Reuters.
UNC Lineberger Cancer Center’s Weekly Seminar Presentation
Wednesday, November 4; 4:00 – 5:00 pm, 00-002 Joseph S. Pagano Conference Room
Stuart A. Aaronson, MD
Professor and Founding Chair Emeritus
Department of Oncological Sciences
Icahn School of Medicine at Mount Sinai
“Translating cancer gene discoveries to the clinic: new insights on potential targets and therapies”
Dr. Aaronson is an internationally recognized cancer biologist, who in early studies established the transformation-competent but replication defective nature of mammalian sarcoma viruses and molecularly cloned many of their oncogenes. He and colleagues implicated retroviral-related oncogenes in human cancer through investigations including the initial detection of their expression in human tumors and critical contributions to the demonstration of their involvement in human cancer.
Dr. Aaronson received his M.D. from UCSF in 1966. He joined the National Institutes of Health in 1967 and became Chief of the Laboratory of Cellular and Molecular Biology at the National Cancer Institute in 1977. He joined Mount Sinai in 1994 and is the Jack and Jane B. Aron Professor and Founding Chair, Emeritus of the Department of Oncological Sciences. He is the recipient of numerous awards including the Distinguished Service Medal from the U.S. Public Health Service, the Rhoads Memorial Award from the American Association of Cancer Research, and the Paul Erhlich Prize from Germany. He is the author of over 530 publications, an inventor on more than 50 patents, and serves on numerous editorial boards and scientific advisory committees.